UroGen Pharma's FDA approval for UGN-102 removes existential risk and validates a contrarian investment stance, driving a sharp stock price recovery. A key investment thesis now hinges on UGN-102's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback